Your browser is no longer supported. Please, upgrade your browser.
Settings
SCYX SCYNEXIS, Inc. daily Stock Chart
SCYX [NASD]
SCYNEXIS, Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own2.10% Shs Outstand50.53M Perf Week4.67%
Market Cap79.33M Forward P/E- EPS next Y-0.60 Insider Trans6.21% Shs Float46.83M Perf Month22.66%
Income-22.00M PEG- EPS next Q-0.20 Inst Own37.80% Short Float5.14% Perf Quarter273.81%
Sales0.30M P/S264.44 EPS this Y-52.30% Inst Trans-11.76% Short Ratio1.85 Perf Half Y27.64%
Book/sh0.65 P/B2.42 EPS next Y17.90% ROA- Target Price5.81 Perf Year1.95%
Cash/sh0.87 P/C1.80 EPS next 5Y- ROE- 52W Range0.35 - 2.15 Perf YTD225.93%
Dividend- P/FCF- EPS past 5Y- ROI-50.20% 52W High-26.98% Beta2.34
Dividend %- Quick Ratio8.80 Sales past 5Y-56.70% Gross Margin- 52W Low348.57% ATR0.12
Employees87 Current Ratio8.80 Sales Q/Q0.00% Oper. Margin- RSI (14)64.07 Volatility9.10% 7.72%
OptionableYes Debt/Eq0.48 EPS Q/Q- Profit Margin- Rel Volume0.32 Prev Close1.57
ShortableYes LT Debt/Eq0.48 EarningsMar 19 BMO Payout- Avg Volume1.30M Price1.57
Recom- SMA2015.57% SMA5037.28% SMA20030.81% Volume419,910 Change0.00%
Jul-11-18Upgrade Needham Hold → Buy $5
Jun-27-18Initiated Maxim Group Buy $6
Oct-24-17Initiated Guggenheim Buy $6
Jul-10-17Initiated ROTH Capital Buy $8.50
May-09-17Downgrade Needham Buy → Hold
Mar-03-17Reiterated RBC Capital Mkts Outperform $15 → $11
Oct-20-16Initiated H.C. Wainwright Buy $14
Oct-07-16Upgrade WBB Securities Buy → Strong Buy $8
Oct-03-16Resumed Brean Capital Buy
Aug-17-16Initiated Guggenheim Buy $15
Aug-09-16Upgrade WBB Securities Speculative Buy → Buy $8
Aug-09-16Reiterated Needham Buy $16 → $10
Mar-28-16Initiated Brean Capital Buy $16
Dec-29-15Initiated WBB Securities Strong Buy $8
Dec-29-15Initiated WBB Securities Speculative Buy $8
Nov-16-15Reiterated RBC Capital Mkts Outperform $18 → $17
Jun-10-15Initiated Needham Buy $16
May-29-14Initiated RBC Capital Mkts Outperform $17
May-29-14Initiated Canaccord Genuity Buy $18
Mar-14-19 04:39PM  SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update PR Newswire +25.40%
Mar-07-19 09:34AM  SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note PR Newswire
Feb-28-19 09:50AM  Do Institutions Own Shares In SCYNEXIS, Inc. (NASDAQ:SCYX)? Simply Wall St.
08:30AM  SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019 PR Newswire
Jan-31-19 09:20AM  4 Biotech Stocks Making Moves On Thursday (1/31/19) ACCESSWIRE +41.67%
Jan-30-19 04:05PM  SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies PR Newswire
Jan-22-19 08:45AM  SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors PR Newswire
Jan-21-19 11:24AM  Does SCYNEXIS, Inc.s (NASDAQ:SCYX) CEO Salary Reflect Performance? Simply Wall St.
Jan-17-19 10:00AM  Antimicrobials Working Group Announces Updates to Leadership Team PR Newswire
Jan-04-19 07:59AM  The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO Benzinga +12.18%
Jan-03-19 04:05PM  SCYNEXIS Provides Year-end Update and Outlines Plans for 2019 PR Newswire
Nov-23-18 08:00AM  Report: Developing Opportunities within ReWalk Robotics, ImmuCell, SCYNEXIS, Fuel Tech, Garrison Capital, and AMREP Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-20-18 08:00AM  SCYNEXIS, Inc. to Present at Upcoming Investor Conferences PR Newswire -7.88%
Nov-13-18 10:25AM  Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates Zacks -5.08%
09:19AM  Scynexis: 3Q Earnings Snapshot Associated Press
09:05AM  SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update PR Newswire
Oct-23-18 09:00AM  SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp PR Newswire
Oct-15-18 09:26AM  SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES) PR Newswire
Oct-01-18 09:25AM  SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week PR Newswire
Sep-26-18 08:00AM  SCYNEXIS to Present an Overview of the Company's Pipeline at IDWeek 2018 PR Newswire
Sep-25-18 08:00AM  SCYNEXIS, Inc. to Present at Upcoming Investor Conferences PR Newswire
Sep-18-18 08:29AM  Who Owns SCYNEXIS Inc (NASDAQ:SCYX)? Simply Wall St.
Aug-29-18 11:52AM  5 Healthcare Stocks That Are Down, But Not Out! InvestorPlace
08:00AM  SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences PR Newswire
Aug-09-18 06:45PM  Scynexis (SCYX) Reports Q2 Loss, Lags Revenue Estimates Zacks
05:43PM  Scynexis: 2Q Earnings Snapshot Associated Press
04:15PM  SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update PR Newswire
Jul-30-18 07:10AM  Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks ACCESSWIRE
Jul-18-18 08:05AM  The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078 PR Newswire
Jul-10-18 04:05PM  SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis PR Newswire -5.71%
Jul-02-18 07:25AM  Complimentary Technical Snapshots on Mylan and Three More Generic Drugs Stocks ACCESSWIRE
Jun-27-18 08:00AM  SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting PR Newswire
Jun-14-18 08:00AM  SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018 PR Newswire +6.67%
Jun-11-18 08:30AM  SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018 PR Newswire
Jun-06-18 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 PR Newswire
08:30AM  SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology PR Newswire
May-24-18 08:30AM  SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018 PR Newswire +8.81%
07:15AM  Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks ACCESSWIRE
May-23-18 08:30AM  SCYNEXIS to Participate in a Panel at the 2018 BIO International Convention PR Newswire
May-08-18 07:11PM  Scynexis: 1Q Earnings Snapshot Associated Press +9.32%
04:20PM  SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update PR Newswire
May-01-18 08:30AM  SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC PR Newswire +9.32%
Apr-23-18 08:00AM  SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis PR Newswire
Apr-20-18 10:17AM  Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-10-18 07:30AM  SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) PR Newswire
Mar-21-18 07:30AM  SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference PR Newswire
Mar-20-18 04:05PM  SCYNEXIS Presents Data at Superbugs and Superdrugs 2018 PR Newswire
Mar-13-18 04:25PM  SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update PR Newswire
Mar-07-18 07:30AM  SCYNEXIS to Present at the 30th Annual ROTH Conference PR Newswire
Mar-06-18 09:25AM  SCYNEXIS Announces Pricing of $30.0 Million Public Offering of Common Stock and Warrants PR Newswire -15.09%
Mar-05-18 04:01PM  SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants PR Newswire
Feb-01-18 08:30AM  SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018 PR Newswire
Jan-11-18 04:05PM  SCYNEXIS to Participate in the Cantor Antibiotics Summit PR Newswire
Jan-04-18 04:05PM  SCYNEXIS Provides Corporate and SCY-078 Pipeline Update PR Newswire
Dec-18-17 04:22PM  ETFs with exposure to SCYNEXIS, Inc. : December 18, 2017 Capital Cube
Nov-28-17 08:00AM  SCYNEXIS to Participate in Upcoming Investor Conferences PR Newswire
Nov-22-17 08:00AM  SCYNEXIS to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-16-17 05:56PM  SCYNEXIS Appoints Scott Sukenick as General Counsel PR Newswire +5.71%
Nov-10-17 12:50PM  ETFs with exposure to SCYNEXIS, Inc. : November 10, 2017 Capital Cube
Nov-09-17 09:19AM  SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 Capital Cube
Nov-07-17 07:06PM  Scynexis reports 3Q loss Associated Press
04:20PM  SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update PR Newswire
Oct-05-17 08:30AM  SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017 GlobeNewswire
Sep-27-17 08:30AM  SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017 GlobeNewswire
Sep-22-17 11:18AM  ETFs with exposure to SCYNEXIS, Inc. : September 22, 2017 Capital Cube
Sep-13-17 06:31PM  What Does SCYNEXIS Incs (SCYX) Share Price Indicate? Simply Wall St.
Aug-31-17 08:42PM  ETFs with exposure to SCYNEXIS, Inc. : September 1, 2017 Capital Cube
09:05AM  SCYNEXIS to Present at Upcoming Investor Conferences GlobeNewswire
Aug-24-17 10:36AM  SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-15-17 08:00AM  THINK FUNGUS - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC) GlobeNewswire
Aug-14-17 08:00AM  SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting GlobeNewswire +6.41%
Aug-08-17 04:25PM  SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update GlobeNewswire
Aug-07-17 09:05AM  SCYNEXIS to Present at the Canaccord Genuity Growth Conference GlobeNewswire
Aug-03-17 04:05PM  SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis GlobeNewswire
Jun-19-17 10:17AM  Antimicrobial Working Group Members to Participate in 2017 BIO International Convention Panel PR Newswire
Jun-15-17 08:30AM  New Study Further Demonstrates In Vitro Activity of SCYNEXIS Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains GlobeNewswire
Jun-14-17 01:48PM  ETFs with exposure to SCYNEXIS, Inc. : June 14, 2017 Capital Cube
Jun-13-17 09:05AM  SCYNEXIS, Inc. to Participate in the 2017 BIO International Convention GlobeNewswire
Jun-05-17 08:30AM  Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078 GlobeNewswire
May-24-17 09:05AM  Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS Lead Agent to Combat Serious and Life-threatening Fungal Infections GlobeNewswire
May-15-17 04:35PM  ETFs with exposure to SCYNEXIS, Inc. : May 15, 2017 Capital Cube
May-12-17 11:55AM  SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube
May-11-17 08:30AM  Potent in vitro Activity of SCYNEXIS SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention (CDC) GlobeNewswire
May-08-17 04:46PM  Scynexis reports 1Q loss Associated Press
04:20PM  SCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation Development Status GlobeNewswire
03:48PM  SHAREHOLDER ANNOUNCEMENT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017 Business Wire
10:49AM  DEADLINE TODAY: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
10:20AM  DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017 - SCYX Accesswire
10:10AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against SCYNEXIS, Inc. (SCYX) & Lead Plaintiff Deadline - May 8, 2017 GlobeNewswire
May-05-17 11:58PM  MAY 8 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
07:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in SCYNEXIS, Inc. of Class Action Lawsuit and Upcoming Deadline - SCYX Accesswire
06:51PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In SCYNEXIS, Inc. To Contact The Firm Before Lead Plaintiff Deadline Business Wire
01:55PM  DEADLINE MONDAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving SCYNEXIS, Inc. and a Lead Plaintiff Deadline of May 8, 2017 Accesswire
May-04-17 07:16PM  MONDAY DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
02:27PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017 - SCYX Accesswire
May-03-17 04:10PM  5-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
02:06PM  DEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In SCYNEXIS, Inc. (Nasdaq: SCYX) To Contact The Firm GlobeNewswire
May-02-17 06:39PM  DEADLINE ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
11:55AM  SCYX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving SCYNEXIS, Inc. and a Lead Plaintiff Deadline of May 8, 2017 Accesswire
10:23AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against SCYNEXIS, Inc. (SCYX) and Lead Plaintiff Deadline - May 8, 2017 Accesswire
SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Taglietti MarcoChief Executive OfficerJan 10Buy0.6925,00017,250480,000Jan 14 09:04 AM
Angulo Gonzalez DavidChief Medical OfficerDec 31Buy0.5012,0005,951121,790Jan 02 11:28 AM
Taglietti MarcoChief Executive OfficerDec 31Buy0.4625,00011,500455,000Jan 02 11:28 AM
Angulo Gonzalez DavidChief Medical OfficerSep 06Buy1.277,0008,890108,790Sep 10 09:09 AM
Taglietti MarcoChief Executive OfficerAug 23Buy1.2925,00032,250429,000Aug 27 08:29 AM
Angulo Gonzalez DavidChief Medical OfficerMar 29Buy1.366,0008,160101,790Apr 02 08:10 AM